ConMed Shows Rising Relative Strength; Still Shy Of Key Benchmark

In a welcome move, ConMed (CNMD) saw its Relative Strength Rating rise from 66 to 71 on Friday.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This exclusive rating from Investor’s Business Daily measures share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock’s price behavior over the trailing 52 weeks compares to all the other stocks in our database.

Decades of market research reveals that the top-performing stocks tend to have an RS Rating of over 80 as they launch their largest runs. See if ConMed can continue to rebound and clear that threshold.

See How IBD Helps You Make More Money In Stocks

ConMed is working on a consolidation with a 147.05 buy point. See if it can break out in heavy trade.

In terms of top and bottom line numbers, ConMed has posted two quarters of rising earnings growth. Sales gains have also moved higher during the same period.

The company holds the No. 19 rank among its peers in the Medical-Products industry group. Bio Rad Labs (BIOB) and Staar Surgical (STAA) are also among the group’s highest-rated stocks.


IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

See How To Reduce Risk, Increase Profits With Swing Trading

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button